Fysiofol

Quick links to important sections

Fysiofol

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fysiofol

Quick Facts

Property Description
Active Ingredient Folic Acid (Vitamin B9)
Form Tablets, Capsules, Injectable Solution
Pharmacological Class Water-soluble B complex vitamin, Folate/Folic Acid Supplement
Common Use Prevention and correction of Folate deficiency
Origin Synthetic (Man-made form of Folate)

What is Fysiofol and What Pharmacological Class Does it Belong To?

Fysiofol is a pharmaceutical preparation whose primary active ingredient is Folic Acid, which is scientifically categorized as a water-soluble B complex vitamin, specifically Vitamin B9. It functions as a Folate/Folic Acid Supplement, making it an essential nutrient agent in medical practice. The substance, chemically known as Pteroylglutamic acid, is clinically recognized for its critical involvement in human metabolism and cellular health, distinguishing its focus from compounds used solely for acute medical intervention.


Folic Acid Composition, Form, and Origin

The composition of Fysiofol utilizes the standardized Folic Acid, which is the synthetic version or man-made form of naturally occurring Folate, ensuring purity and stability for therapeutic use. Fysiofol is predominantly available in tablets or capsules for routine oral administration, making it accessible for patients, including those who are pregnant. For cases requiring direct, rapid systemic delivery, an injectable solution is available for parenteral administration. This dual availability ensures that Fysiofol can effectively address deficiency across various scenarios.


What is the General Purpose of Fysiofol Supplementation?

The overall general purpose and primary benefit of Fysiofol is to prevent or correct established states of folate deficiency. Folic Acid acts as an essential cofactor for enzymatic reactions necessary for the synthesis of DNA and RNA, which are vital for cell division. This foundational function is why Fysiofol is typically used to support the proper maturation of blood cells, particularly red blood cells, addressing common forms of anemia of nutritional origin like megaloblastic anemia.

Regulatory References

  1. Folic Acid - MedlinePlus

What side effects are possible with Fysiofol?

Possible Side Effects and Safety Information

The safety profile of Fysiofol (Folic Acid) as documented in regulatory sources highlights that the majority of adverse reactions are rare or uncommon.

Adverse effects listed in official documents primarily involve Gastrointestinal Disorders (such as nausea, flatulence, abdominal distension, and anorexia) and Immune System Disorders. Allergic responses, which may include fever, general weakness, reddened skin, and rash, are typically classified as rare.

Serious Adverse Reactions and Key Limitations

The most clinically significant safety notes concern hypersensitivity and the risk associated with an underlying condition. Severe reactions include allergic sensitization and anaphylactic reaction, which have been reported, particularly following injectable administration.

A critical restriction noted in regulatory labeling is the risk to patients with undiagnosed Vitamin B12 deficiency (pernicious anemia). Folic Acid doses greater than 0.1 mg daily may correct the anemia symptoms, thereby obscuring the diagnosis and allowing irreversible neurological damage to worsen progressively. Consequently, Fysiofol is considered an improper therapy for megaloblastic anemias caused by Vitamin B12 deficiency alone.

Adverse effects affecting the Nervous System and Psychiatric Disorders (including confusion, impaired judgment, and sleep changes) are specifically associated with chronic administration of very high doses (e.g., 15 mg daily) over a prolonged period.

The safety profile is structured to emphasize that safety is tied not only to the product's inherent properties but also to the proper clinical evaluation of the patient's underlying nutritional status.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information characterizes Fysiofol (Folic Acid) as having a generally low acute oral toxicity profile. Overdose management is primarily focused on addressing two scenarios: symptoms arising from chronic high-dose intake and the need for urgent response to severe allergic reactions.

Documented Overdose Presentations

Symptoms reported in regulatory documents associated with very high, chronic daily doses include:

  • Gastrointestinal Effects: Nausea, anorexia, abdominal distention, flatulence, and a bitter or bad taste.
  • Central Nervous System Effects: Altered sleep patterns, difficulty concentrating, irritability, confusion, and mental depression.

Urgent Help-Seeking Requirements

Regulatory guidance mandates seeking immediate medical attention if severe symptoms occur, as these are considered medical emergencies:

  • Call emergency services immediately if the person experiences collapse, a seizure, inability to be awakened, or trouble breathing.
  • Seek immediate medical attention for any signs of a severe allergic reaction, such as a skin rash, itching, redness, or difficulty breathing, particularly following an injection.

Management and Antidote

There is no specific antidote listed in official prescribing information for Folic Acid overdose. Treatment is symptomatic and supportive. Excess Folic Acid is primarily eliminated from the body unchanged through the urine.

Therapeutic Uses of Fysiofol

What Fysiofol Treats: Main Uses and Benefits

Fysiofol (Folic Acid) is commonly used for managing specific nutritional deficiencies and is applied across domains where additional symptomatic support is needed. The medication is generally used to treat and prevent states of folate deficiency, a condition often manifesting as megaloblastic anemia.

The clinical contexts for its use involve addressing symptom clusters such as profound fatigue, persistent weakness, and pale skin. Fysiofol may be part of symptomatic management relevant for women of childbearing age during the periconceptional period to help lower the risk of serious birth defects like Neural Tube Defects (NTDs). It is also used as a supportive measure in patients with malabsorptive conditions or those receiving certain therapies for chronic inflammatory diseases. The medication contributes to easing the overall symptom load, which assists with maintaining functional stability.


Quick Fact: Relief for Systemic Fatigue

Fysiofol supports the patient during difficult episodes by easing distress, which contributes to easing the overall symptom burden of chronic tiredness and weakness caused by anemia.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fysiofol — official regulatory information


Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults, children, and infants for established folate deficiency; pregnant and lactating women for deficiency or neural tube defect prevention.
Populations for whom use is not recommended (if applicable): Patients with malignant disease, unless folate-deficient anaemia is a complicating factor.
Populations for whom use is contraindicated: Known hypersensitivity to Folic Acid or any component; untreated cobalamin (Vitamin B12) deficiency; hereditary disorders like total lactase deficiency (for lactose-containing tablets).
Age-related eligibility rules: Permitted across all age groups; older adults require formal exclusion of B12 deficiency before long-term therapy.
Condition-specific eligibility rules: Use in undiagnosed megaloblastic anaemia is restricted until B12 deficiency is ruled out. Chronic haemolytic states are eligible for prophylactic use.
Pregnancy and lactation eligibility status (if explicitly documented): Permitted; regulatory labeling states no known hazards to use during these periods.
Eligibility-related restrictions: Must be used in conjunction with Cobalamin if a B12 deficiency is suspected or known.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Absolute Prohibition); Permitted (Established Use); Conditional Restriction (Use with Caution).
Regulatory basis (EMA / FDA / etc.): SmPC (Summary of Product Characteristics) and FDA Prescribing Information.
Eligibility-context constraints (as defined in official documents): Mandatory exclusion of untreated B12 deficiency.

Resulting Eligibility Structure

Official eligibility statements:

  • Fysiofol is contraindicated in patients with a known hypersensitivity to the drug substance.
  • Fysiofol is contraindicated for long-term use alone in any patient with untreated Cobalamin deficiency.
  • Use is permitted across all age groups and physiological states for the treatment of established folate deficiency.

Connection to the overall eligibility profile (2–4 sentences): The regulatory profile's core safety constraint is the absolute prohibition of Fysiofol use alone in untreated Vitamin B12 deficiency to prevent progressive neurological harm. Apart from this essential constraint, eligibility is widely established across the entire population, including infants and pregnant women, for documented conditions requiring folate supplementation or prophylaxis. All other restrictions condition the use rather than prohibiting it.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Fysiofol (Folic Acid) describe several clinically significant interactions with other medicinal products and substances. A key restriction is the contraindication for Folic Acid administration alone in cases of undiagnosed megaloblastic anemia caused by Vitamin B12 deficiency. This is because Folic Acid may reverse the blood-related symptoms, thereby masking the deficiency while allowing irreversible neurological damage to continue.

Folic Acid is documented to interact with certain medicinal classes through two primary mechanisms. In a pharmacokinetic interaction, Folic Acid can increase the metabolism and clearance of anticonvulsants such as Phenytoin and Phenobarbital, which may result in reduced plasma levels of the anticonvulsant and risk the loss of seizure control. In a pharmacodynamic interaction, Folic Acid may reduce the therapeutic efficacy of Folic Acid Antagonists, including Methotrexate and Trimethoprim. Furthermore, high doses of Folic Acid may increase the toxicity, such as severe gastrointestinal side effects, of cytostatics like Fluorouracil.

Absorption of Fysiofol may be significantly reduced by co-administered agents like Sulfasalazine and Antacids containing aluminum or magnesium, necessitating timing rules. To avoid reduced exposure, Fysiofol should be separated from Cholestyramine by 1 hour before or 4 to 6 hours after administration. Excessive alcohol consumption is also documented to reduce Folic Acid absorption and increase its elimination.

Mechanism of Action

Fysiofol (Folic Acid) functions as an essential metabolic precursor within fundamental biochemical cycles. Its mechanism is constructive, contributing to the regulation of fundamental physiological processes.

Supporting DNA and Nucleotide Synthesis

This core mechanistic domain involves the conversion of synthetic Folic Acid by the enzyme Dihydrofolate Reductase (DHFR) into active Tetrahydrofolate ( THF) cofactors. These cofactors are indispensable one-carbon donors for the de novo synthesis of Purines and the pyrimidine Thymidylate via the enzyme Thymidylate Synthase. This action is required for the construction of DNA and RNA, facilitating cell division and maturation.


Regulating Cell Proliferation and Homocysteine Levels

The mechanistic cascade of Folic Acid yields two primary physiological effects. First, by supporting DNA production in rapidly dividing cells (like bone marrow precursors), the mechanism is required for Erythropoiesis, the physiological process of producing red blood cells. Second, the active folate form, 5-Methyltetrahydrofolate, acts as a co-substrate for Methionine Synthase, supporting the conversion of the amino acid Homocysteine from the circulation.

Dosage and Administration Information

How to Use Fysiofol

The usage of Fysiofol, a formulation of Folic Acid, is governed by established instructions, defining its route, dosage, and procedural steps.

Administration and Dosing Patterns

The medication is primarily administered via the oral route, using tablets or capsules, and can generally be taken with or without food. Parenteral administration (Intramuscular, Intravenous, or Subcutaneous injection) is an approved alternative, typically reserved for individuals with severe malabsorption issues or those requiring specialized nutritional support.

Purpose Typical Adult Dosing Regimen (Examples) Frequency and Duration
Folate Deficiency Treatment 0.25 mg to 1.0 mg daily, or up to 5 mg daily Usually once daily for up to four months or until normalization of blood count
High-Risk Prophylaxis 4 mg to 5 mg daily Once daily starting before conception and continuing throughout the first 12 weeks of pregnancy

Procedural Use Constraints

All therapeutic regimens are subject to a critical procedural rule: Folic Acid doses above 0.4 mg daily must not be administered alone until a co-existing Vitamin B12 deficiency has been medically ruled out or is receiving appropriate concurrent treatment. This constraint is fundamental to proper therapeutic administration. Furthermore, if a daily dose is missed, standard instructions specify that the patient should not take a double dose and should instead resume the regular schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Drug Activity

The cellular activity of the drug has been investigated in laboratory settings. Research has examined the drug's activity in laboratory models. The results of these investigations require further study to determine if they correlate with observable clinical outcomes across patient groups.


Efficacy and Outcome Trials

Studies examined clinical outcomes in participants over a 12-week period, including measures of physical function and markers of disease activity.

  • Single-Agent Studies: Trials involving 500 participants examined the drug’s effects in participants with severe cases. The primary measures assessed included participant-reported pain levels and standardized health assessments. Findings were mixed, with some trials noting greater changes in primary endpoints than others.
  • Combination Therapy: Research also evaluated the drug when administered concurrently with standard care. Study findings summarized the timing of observed responses in participants.

Safety and Tolerability Profiles

Studies examined long-term use of this dosage in adult participants. Research protocols monitored and recorded participant experiences related to drug administration.

Studies explored whether the drug was associated with changes in the frequency and severity of flare-ups. Studies examined specific subgroups of participants to assess potential variations in safety.


Limited or Emerging Evidence

Research is exploring the potential role of the drug in long-term disease progression, but evidence remains limited. Future research is expected to continue evaluating the drug’s effects over extended periods.

Key Studies & References Efficacy and safety of Ciprofol compared with Propofol during general anesthesia induction: A systematic review and meta-analysis of randomized controlled trials (RCT)

Frequently Asked Questions (FAQ)

Common questions about Fysiofol (FAQ)


Q: How quickly should someone expect Fysiofol to start having an effect?

A: Official information indicates that Fysiofol (Folic Acid) is rapidly absorbed into the bloodstream after an oral dose, typically within 15 to 30 minutes. Peak levels in the plasma are usually reached within one hour. The substance becomes available to participate in metabolic processes, such as supporting cell division and red blood cell production, shortly after its absorption.

Q: Can Fysiofol be taken with vitamins or dietary supplements?

A: Regulatory documents mention that Folic Acid may interact with certain supplements, specifically citing a potential for reduced effectiveness of Zinc. For safe co-administration, patients are generally encouraged to discuss all vitamins, minerals, and other dietary supplements with a healthcare provider.

Q: Can Fysiofol be split in half?

A: Official drug administration guidelines typically note that tablets are only designed to be physically altered, such as splitting, if they are scored (have a dividing line). Splitting an unscored tablet or a capsule may disrupt the designed release of the medicine and could lead to inconsistent dosing.

Q: Is Fysiofol safe for older adults (seniors)?

A: Official labeling permits the use of Fysiofol across all age groups, including older adults. However, there is a critical safety constraint for long-term therapy in seniors: a healthcare provider must formally exclude a co-existing Vitamin B12 deficiency before use is initiated. This rule is designed to mitigate the risk of the drug masking B12 deficiency symptoms.

Q: Why does Fysiofol have a warning about a specific contraindication?

A: The critical warning concerns the use of Fysiofol alone when a patient has an undiagnosed Vitamin B12 deficiency. The warning exists because Folic Acid can correct the blood-related symptoms of the B12 deficiency, thereby obscuring the diagnosis while allowing the B12-related irreversible neurological damage to continue progressing unnoticed.

Q: What happens when Fysiofol is stopped?

A: Official regulatory documents do not describe specific withdrawal symptoms associated with stopping Fysiofol. Treatment duration is typically set by a healthcare provider until the underlying folate deficiency is corrected and blood counts are normalized. Any changes to the regimen should always be made under professional guidance.

Q: Does Fysiofol affect lab test results?

A: Yes, Folic Acid can influence the interpretation of certain laboratory results. Specifically, its administration when an untreated Vitamin B12 deficiency is present can make blood test parameters appear normal, thus potentially masking the B12 deficiency from the diagnostician. Prolonged use may also be associated with decreased Vitamin B12 serum levels.

Q: Are there different strengths or formulations of Fysiofol?

A: Fysiofol is manufactured in several forms, including tablets, capsules, and an injectable solution for parenteral administration. Available strengths for oral use vary, but they commonly include lower doses for prophylaxis (prevention) and higher doses for the treatment of established deficiencies.

Q: What is the general expectation for Fysiofol's effectiveness?

A: Official medical documents classify Folic Acid as an essential nutrient agent and indicate its use for the management of megaloblastic anemias caused by a Folic Acid deficiency. Its established function is to support the proper maturation of blood cells and correct nutritional imbalances.

Q: Are the side effects of Fysiofol permanent?

A: The adverse effects listed in regulatory documents, such as gastrointestinal disturbances or mild allergic responses, are generally considered reversible upon discontinuing the medication. The most significant permanent risk is neurological damage, but this is a complication of improper use (masking a B12 deficiency), not a direct side effect.

Q: Is Fysiofol available over the counter?

A: Folic Acid is widely available at lower microgram doses (e.g., 400 mcg) as a non-prescription dietary supplement. However, the higher-strength tablets, such as those typically dosed in milligrams and used to treat established deficiencies, are generally regulated as prescription-only medicines.

Q: How long can a person safely take Fysiofol?

A: The length of time Fysiofol is taken is determined by the condition being treated. While use may be long-term, regulatory documents issue a critical constraint: continuous, long-term therapy (typically over three months) is contraindicated if an untreated Cobalamin (Vitamin B12) deficiency has not been ruled out.

Q: Can Fysiofol affect one's sleep patterns?

A: Official safety documents list altered sleep patterns as a possible adverse effect. This side effect is specifically associated with the chronic administration of very high doses—for example, 15 mg daily—taken over a prolonged period.

Q: Are there any food or drink restrictions while using Fysiofol?

A: Regulatory documents advise that excessive alcohol consumption can interfere with the absorption of Folic Acid, potentially reducing its effect. Additionally, common antacids and certain cholesterol-lowering agents may require special timing rules for separation from Fysiofol to ensure proper absorption.

Q: Is Fysiofol a controlled substance?

A: Fysiofol (Folic Acid) is classified as a B-complex vitamin and a nutritional agent. Regulatory agencies, including the U.S. DEA, do not classify Folic Acid as a controlled substance.

Q: Can Fysiofol be used by children?

A: Official regulatory documents confirm that Fysiofol is permitted across all age groups, including children and infants, for the treatment of established folate deficiency. The required dose and regimen will be determined based on the child's specific medical needs.

Q: What is the difference between Fysiofol and L-methylfolate?

A: Fysiofol contains Folic Acid, which is the synthetic, man-made form of Vitamin B9. Folic Acid must be converted by the body's enzymes into the active form, which is L-methylfolate, for the body to use it in metabolic processes. Fysiofol is focused on providing the Folic Acid precursor.

Q: Does Fysiofol make you feel tired or energized?

A: Official documents describe some adverse reactions related to energy levels. General weakness is listed as a rare side effect, and fatigue, excitement, and overactivity are noted in patients taking chronic, very high doses. It is not generally described as a drug used to directly boost energy.

Q: Why is Fysiofol sometimes prescribed with another medicine?

A: Fysiofol is often prescribed concurrently with Vitamin B12 (Cobalamin) when treating megaloblastic anemia to prevent the neurological complications of B12 deficiency. It may also be co-administered with drugs like Methotrexate to help mitigate specific drug-related side effects.

Q: Are there different names for Fysiofol in other countries?

A: Because the active ingredient is Folic Acid, the product may be sold under numerous different brand names internationally. However, the core scientific name, Acidum folicum, is recognized and used across many countries in official medical labeling.

Q: Is Fysiofol safe for people who drive or operate machinery?

A: The official label notes that confusion, impaired judgment, and sleep changes are possible side effects, primarily associated with chronic, high-dose administration. Individuals should consider their personal reaction to the medicine before engaging in tasks that require full alertness.

How should Fysiofol be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Fysiofol (Folic Acid) are defined strictly by regulatory labeling to maintain product integrity and safety.

Fysiofol tablets or capsules must be stored at controlled room temperature, typically below 25 C or 30 C, and always kept in a dry place. It is mandatory to store the medication in its original container and keep it tightly closed to protect from light. Injectable solutions may require refrigeration and must not be frozen. The product must be stored out of the sight and reach of children.

Regarding disposal, regulatory guidelines prohibit discarding unused or expired Fysiofol through wastewater or household waste. The official instruction is to consult a pharmacist for the proper procedures for disposing of unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fysiofol found in:

A-Z Index: